** Brokerage UBS upgrades healthcare conglomerate CVS Health CVS.N to "buy" from "neutral," raising PT to $79 from $67
** New PT represents a ~13.2% upside to the stock's last close
** Shares of CVS up 2.2% at $70.1 premarket
** UBS says CVS has managed its Medicare Advantage plans well, giving the brokerage more confidence in its future performance
** UBS believes CVS will reduce its debt by late 2026, allowing for more share buybacks and further earnings growth
** UBS says it does not expect any major negative changes from drug pricing rules or its Star ratings in the near term
** As of last close, CVS stock up 52.8% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。